RTS,S /AS01 (Mosquirix), developped by GSK, is the first licensed malaria vaccine. The WHO prequalified this vaccine in July 2022. In a Phase III trial conducted in 7 countries, RTS,S/AS01 demonstrated an efficacy of 30-50% against malaria.
The introduction of RTS,S /AS01 in African countries began in early 2024, starting in Cameroon and Burkina Faso. Real-world effectiveness and impact of the RTS,S/AS01 vaccine is the focus of the EDCTP2-funded Malaria Vaccine Pilot Evaluation – Case Control (MVPE-CC) Project.